Abstract:Objective: To investigate the changes in lymphocyte subsets in patients with advanced non-small-cell lung cancer (NSCLC) before and after the treatment using endostar combined with chemotherapy.Methods: Eighty-six patients with advanced NSCLC who were treated in the oncology department of our hospital from June 2018 to February 2019 were randomly selected and divided into a control group and study group using the random-number expression method, with 43 patients in each group. The control group was treated using chemotherapy (docetaxel + carboplatin). The patients in the study group were treated with endostar on the basis of the control group, and both groups were treated for 6 weeks. The clinical efficacy of the two groups was evaluated. The levels of vascular endothelial growth factor (VEGF), matrix maalloproteinase-2 (MMP2), and matrix metalloproteinase-9 (MMP-9) were measured using EL1SA. The lymphocyte subsets (CD3+, CD4+, and CD4+/CD8+) and natural killer cells (NK) were measured by flow cytometry. The adverse reactions of the two groups were compared.Results: After treatment, the objective effective rate and disease-control rate of the two groups were 65.12% and 8139%; 83.72% and 9535%, respectively, which were significantly higher in the study group than in the control group (P<0.05). After treatment, the levels of VEGF, MMP-2, and MMP-9 in the two groups were significantly lower than those before treatment, and the indexes in the study group were significantly lower (P<0.05). After treatment, the levels of NK, CD3+, CD4+, and CD4+/CD8+ in the two groups were significantly higher than those before treatment, the levels of CD8+ in the study group were significantly higher than those in the control group, and the levels of CD8+ in the study group were significantly lower than those in the control group (P<0.05). The incidence of adverse reactions was 25.58% in the study group and 48.84% in the control group. The incidences of adverse reactions in the study group were significantly lower than those in the control group (P<0.05).Conclusion: Endostar combined with chemotherapy has a significant clinical effect in the treatment of advanced NSCLC. It can reduce the levels of VEGF, MMP-2, and MMP-9 in patients with advanced NSCLC; inhibit tumour invasion and metastasis; and improve the immune function of the body in a safe and reliable manner.

Effect of highly effective anti-retroviral therapy combined with chemotherapy on CD4+ counts and quality of life score in patients with HIV infection and lung cancer

Effect of highly effective antiretroviral therapy combined with chemotherapy on bone marrow suppression and quality of life scores in patients with human immunodeficiency virus infection in lung cancer

The Impact of Highly Active Antiretroviral Treatment on the Blood Profiles of Patients with Acquired Immune Deficiency Syndrome

[Individualized Comprehensive Therapy for the Lung Cancer Patients with HIV Infection].

The Effect of Highly Active Antiretroviral Therapy on Liver Function in Human Immunodeficiency Virus-Infected Pediatric Patients with or Without Hepatitis Virus Co-Infection

P1.03-046 A Retrospective Analysis of Correlation Between Cytokines in TME and Therapeutic Effect of Advanced Lung Cancer Chemotherapy in China

Changes And Significance Of Lymphocyte Subsets In Patients With Advanced Nsclc Before And After Endostar Combined Chemotherapy

High-Quality Nursing Combined with Nutritional Intervention Improves Lung Function, Quality of Life, and Compliance of Patients with Lung Cancer After Chemotherapy

[Effect of chemotherapy on the quality of life of lung cancer patients]

Effect of chemotherapy combined with amino acid on quality of life in elderly patients with non-small cell lung cancer

Clini cal observation on clinical efficacy and prognosis of surgical treatment of non-small-cell lung cancer pa-tients infected with HIV

Efficacy and safety of concurrent anti-tuberculosis treatment and chemotherapy in lung cancer patients with co-existent tuberculosis

Quality of Life and Management Project for Patients with Advanced Lung Cancer

Clinical effect of Modified Buzhongyiqi Tang plus Shashenmaidong Tang combined with chemotherapy on advanced non-small cell lung cancer

Effect of Nursing Method of Psychological Intervention Combined with Health Education on Lung Cancer Patients Undergoing Chemotherapy

The effect of nursing intervention combined with PD-1 inhibitor on platelets, white blood cells, tumor markers and quality of life in patients with lung cancer

Outcome in patients with HIV-associated Hodgkin lymphoma treated with chemotherapy using Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine in the combination antiretroviral therapy (cART) era: results of a multicenter study from China

Clinical effect of self-efficacy intervention on quality of life in patients with lung cancer chemotherapy

[Evaluation on the Highly Active Anti-Retroviral Therapy in 181 AIDS Patients].

The impact of chemotherapy on quality of life in advanced-stage lung cancer patients